Ultragenyx Pharmaceutical Inc (RARE)

Industry Biotechnology

This stock can be held in an Investment ISA and an Investment Account

Sell

$20.07

Buy

$22.50

arrow-up$1.03 (+4.81%)

Prices updated at 03 Apr 2026, 00:48 EDT

Prices minimum 15 mins delay

Prices in USD

Ultragenyx Pharmaceutical Inc is biopharmaceutical company. It is engaged identification, acquisition, development and commercialization of novel products for treatment of rare & ultra-rare diseases, with a focus on debilitating genetic diseases.

NASDAQ

0.18%

NASDAQ

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

Mr. Daniel G. Welch

CEO

Dr. Emil D. Kakkis, M.D.,PhD

Most recent earnings

31 Dec 2025

Fiscal year end

31 Dec 2025

Employees

1,371

Head office

60 Leveroni Court

Novato

United States

94949

+1 415 483-8800

dkeatley@ultragenyx.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Dr. Deborah L. Dunsire,M.D. Independent Director	0.07m
Mr. Matthew K. Fust Independent Director	0.08m
Dr. Emil D. Kakkis, M.D.,PhD Director, President and Chief Executive Officer	0.86m
Mr. Daniel G. Welch Chairman of the Board	0.10m
Mr. Michael A. Narachi Independent Director	0.08m
Mr. Theodore A. Huizenga Senior Vice President, Corporate Controller and Chief Accounting Officer	-
Ms. Karah Parschauer, J.D. Chief Legal Officer and Executive Vice President, Corporate Affairs	0.59m
Mr. Dennis Karl Huang Chief Technical Operations Officer and Executive Vice President, Gene Therapy Operations	-
Mr. John Richard Pinion, II Chief Quality Officer and Executive Vice President, Translational Sciences	-
Dr. Eric Crombez, M.D. Executive Vice President and Chief Medical Officer	0.63m
Dr. Shehnaaz Suliman, M.B.A.,M.D.,M.Phil Independent Director	0.07m
Mr. Erik Harris Chief Commercial Officer and Executive Vice President	0.62m
Mr. Howard Horn Chief Financial Officer and Executive Vice President, Corporate Strategy	0.60m
Dr. Corazon Dating Sanders, PhD Independent Director	0.07m
Dr. Amrit Ray, M.B.A.,M.D. Independent Director	0.07m

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Vanguard Group Inc	10,263,815
JPMorgan Chase & Co	8,022,858
BlackRock Inc	6,425,263
State Street Corp	3,692,487
Sands Capital Management, LLC	3,485,724

Director dealings

Date chevron-l-regular chevron-r-regular	Action
29 Dec 2025	-
10 Dec 2025	-
13 Oct 2025	-
18 Sep 2025	-
12 Sep 2025	-
05 Sep 2025	-
20 Jun 2025	-
15 May 2025	-
15 May 2025	-
15 May 2025	-
15 May 2025	-
15 May 2025	-
15 May 2025	-
15 May 2025	-
15 May 2025	-
15 May 2025	-
15 May 2025	-
15 May 2025	-
15 May 2025	-
15 May 2025	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.